Market Cap : 245.77 M | Enterprise Value : 167.28 M | PE Ratio : At Loss | PB Ratio : 3.00 |
---|
NAS:VTGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:VTGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. VistaGen Therapeutics's annualized return on capital (ROC %) for the quarter that ended in Dec. 2021 was -539.20%.
As of today (2022-05-18), VistaGen Therapeutics's WACC % is 8.25%. VistaGen Therapeutics's ROC % is -542.17% (calculated using TTM income statement data). VistaGen Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.
The historical data trend for VistaGen Therapeutics's ROC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VistaGen Therapeutics's annualized Return on Capital (ROC %) for the fiscal year that ended in Mar. 2021 is calculated as:
ROC % (A: Mar. 2021 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (A: Mar. 2020 ) | + | Invested Capital (A: Mar. 2021 )) | / count ) |
= | -17.934 * ( 1 - -0.02% ) | / | ( (4.565 | + | 5.951) | / 2 ) |
= | -17.9375868 | / | 5.258 | |||
= | -341.15 % |
where
Invested Capital | (A: Mar. 2020 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 5.772 | - | 2.398 | - | ( 1.355 | - | max(0, 2.771 | - | 1.58 | + | 1.355 | )) |
= | 4.565 |
Invested Capital | (A: Mar. 2021 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 108.281 | - | 2.401 | - | ( 103.108 | - | max(0, 4.189 | - | 104.118 | + | 103.108 | )) |
= | 5.951 |
VistaGen Therapeutics's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2021 is calculated as:
ROC % (Q: Dec. 2021 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Sep. 2021 ) | + | Invested Capital (Q: Dec. 2021 )) | / count ) |
= | -42.16 * ( 1 - 0% ) | / | ( (7.877 | + | 7.761) | / 2 ) |
= | -42.16 | / | 7.819 | |||
= | -539.20 % |
where
Invested Capital | (Q: Sep. 2021 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 100.5 | - | 4.098 | - | ( 93.627 | - | max(0, 7.912 | - | 96.437 | + | 93.627 | )) |
= | 7.877 |
Invested Capital | (Q: Dec. 2021 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 90.536 | - | 2.426 | - | ( 83.7 | - | max(0, 6.421 | - | 86.77 | + | 83.7 | )) |
= | 7.761 |
Note: The Operating Income data used here is four times the quarterly (Dec. 2021) data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, VistaGen Therapeutics's WACC % is 8.25%. VistaGen Therapeutics's ROC % is -542.17% (calculated using TTM income statement data). VistaGen Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Thank you for viewing the detailed overview of VistaGen Therapeutics's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Saxe Jon S | director | FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076 |
Dotson Jerrold Duane | officer: VP, CFO AND SECRETARY | 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035 |
Singh Shawn | director, officer: CHIEF EXECUTIVE OFFICER | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Snodgrass H. Ralph | director, officer: PRES./CHIEF SCIENTIFIC OFFICER | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Smith Mark Alan | officer: CHIEF MEDICAL OFFICER | 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Mcpartland Mark A. | officer: VP CORPORATE DEVELOPMENT | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Gin Jerry B | director | 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080 |
Underdown Brian J. | director | C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000 |
Cunningham Ann Michelle | director | 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335 |
Rice A. Franklin | officer: VP CORPORATE DEVELOPMENT | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Bonfiglio Gregory A. | director | 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080 |
Platinum Long Term Growth Vii, Llc | 10 percent owner | 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019 |
Cato Holding Co | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Cato Allen Easley | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Jones Stephanie | director, 10 percent owner, officer: PRESIDENT | 13834 W. HOYT ROAD RATHDRUM ID 83858 |
From GuruFocus
Other Sources
By Seekingalpha 2021-01-24
By Zacks 2021-08-12
By Fool 2021-06-30
By Seekingalpha 2021-11-10
By Zacks 2021-02-11
By Zacks 2022-04-05
By tipranks.com 2022-02-13
By Zacks 2021-10-20
By Zacks 2021-11-10
By Zacks 2022-02-10
By Seekingalpha 2021-06-29
By Seekingalpha 2022-02-10
By Zacks 2021-03-11